Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).

Christopher P. Venner, Sonja Zweegman, Shaji Kumar et al. Jun 01, 2026 pp. 7569-7569 10.1200/jco.2026.44.16_suppl.7569

7569 Background: MAIA and CEPHEUS trials demonstrated that daratumumab (Dara) with standard of care (SOC) VRd or Rd signif...

Comparing induction strategies in acute myeloid leukemia: 10-year real-world experience with 7+3 and HMA/venetoclax.

Chandra Kakarala, Rafeh Safdar, Reema Anjum et al. Jun 01, 2026 pp. 6524-6524 10.1200/jco.2026.44.16_suppl.6524

6524 Background: Hypomethylating agents (HMA) combined with venetoclax are the standard of care for AML in adults ineligib...

A pragmatic, hybrid observational study evaluating the effectiveness of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 3+ solid tumors: DESTINY-PanTumor04.

Bradley J. Monk, Bradley Corr, Lin Mei et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps11202

TPS11202 Background: Patients with advanced or metastatic HER2 IHC 3+ solid tumors have limited treatment options beyond f...

Phase I study of zeaxanthin alone or in combination with pembrolizumab in metastatic solid tumors.

Philip Adam Friedlander, Eleonora Teplinsky, Kevin C. Wood et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2696

TPS2696 Background: Zeaxanthin is a carotinoid synthesized by plants that accumulates via dietary intake in the macula. Pr...

Racial differences in survival and prognostic factors among patients with mycosis fungoides and Sézary syndrome: A systematic review and meta-analysis.

Mohammed Baker, Abdelrahman Hasan, Melaad Alshaikh Yousef et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19112

e19112 Background: Mycosis Fungoides (MF) and its leukemic variant, Sezary Syndrome (SS), are the most common forms of cut...

New options for platinum-resistant ovarian cancer: Are we in the right direction?

Laura Ramos, Deolinda Pereira, Miguel Henriques Abreu Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17566

e17566 Background: Ovarian cancer (OC) is the deadliest gynecologic cancer, often diagnosed in advanced stages. Even with...

Desmocolin-3–directed immunotherapy in recurrent/metastatic head and neck squamous cell carcinoma.

Ranjan Das, Antara Sanyal, Swaraj Shankar Satpathy et al. Jun 01, 2026 pp. 2503-2503 10.1200/jco.2026.44.16_suppl.2503

2503 Background: Recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are aggressive tumors. In p...

Impact of an audiovisual educational intervention on gastric cancer knowledge and health literacy in a Mexican population.

Esli Nájera Samaniego, Edith Araceli Fernandez-Figueroa, Juan Carlos Falcon et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22533

e22533 Background: Gastric Cancer (GC) remains a major global health burden, with rising incidence among individuals under...

Sulfidogenic bacteria and the risk of colorectal cancer.

Darren Lee, Nicholas Ollberding, Qing Duan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15727

e15727 Background: Dietary patterns rich in specific sulfur-containing foods that can be metabolized into hydrogen sulfide...

CLEAR-ACCESS: Barriers and facilitators to accessing symptom support among culturally and linguistically diverse cancer patients receiving treatment.

Polly Dufton, Amelia Hyatt, Stephanie Best et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13520

e13520 Background: Patients from culturally and linguistically diverse (CALD) backgrounds experience inequities in cancer...

Palliative care engagement, advance care planning, and healthcare utilization in hepatobiliary malignancies.

Carlotta Pazzi, Royce Lee, Jiayun Lu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24046

e24046 Background: Although advance care planning (ACP) is central to goal-concordant oncology care, its implementation in...

Practice disparities in palliative care utilization across different solid malignancies in the United States: Geographic trends and impact on hospital outcomes.

Jonathan Kutcher, Jayalekshmi Jayakumar, Arya Mariam Roy Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24090

e24090 Background: Palliative care is a specialized approach for patients with life limiting illness. Utilization disparit...

A meta-analysis and systematic review of cardiac adverse events in patients with HER2-altered non–small cell lung cancer (NSCLC) enrolled in clinical trials.

Gabriel Cavalcante Lima Chagas, Amanda Ribeiro Rangel, Bruno Lins de Souza et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24026

e24026 Background: HER2 inhibitors showed meaningful clinical activity in HER2-altered NSCLC. HER2 inhibitors-related card...

Updated efficacy and safety of SHR-1501, an IL-15RαFc superagonist, with or without Bacille Calmette Guerin (BCG) for high-risk non-muscle invasive bladder cancer (NMIBC): A phase 1/2 study.

Zhisong He, Yuke Chen, Wei Xue et al. Jun 01, 2026 pp. 4626-4626 10.1200/jco.2026.44.16_suppl.4626

4626 Background: SHR-1501, an IL-15 agonist fusion protein composing of a humanized antibody Fc region fused with IL-15 an...

S2433: Randomized phase III study of second-line chemotherapy with or without panitumumab for KRAS wild type, locally advanced, or metastatic pancreatic adenocarcinoma.

Rachael A. Safyan, Sarah Colby, Harshabad Singh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps4264

TPS4264 Background: Pancreatic ductal adenocarcinoma (PDA) is characterized by driver mutations in KRA...

Quantum mechanics-based multi-tensor AI/ML as predictor of patients' overall survival, gene targets, and drug responses from their glioblastoma tumors' whole genomes.

Orly Alter, Sri Priya Ponnapalli, Marissa Coppola et al. Jun 01, 2026 pp. 3020-3020 10.1200/jco.2026.44.16_suppl.3020

3020 Background: The drug failure rate has increased to ~95%, despite the growth in targeted therapies. As clinical trials...

Response to HiDAC/mitoxantrone/venetoclax (HMV) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).

Apoorva Ravichandran, Miles Thomas, Rafael Madero Marroquin et al. Jun 01, 2026 pp. 6527-6527 10.1200/jco.2026.44.16_suppl.6527

6527 Background: Outcomes for patients (pts) with R/R AML are dismal, especially after failure of Venetoclax (Ven)-based r...

A phase 1 study of the safety, pharmacokinetics, and pharmacodynamics of intermittent oral PRTX007, an IRF7-biased TLR7 agonist prodrug.

James Richard Appleman, Curtis Scribner, Andrew Sharabi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14606

e14606 Background: Systemically active toll-like receptor 7 (TLR7) agonists have demonstrated immune-activating potential...

First results from the phase 1/2 LINKER-AL2 trial of linvoseltamab (LINVO) in patients (pts) with relapsed or refractory (RR) systemic light chain (AL) amyloidosis.

Ashutosh D. Wechalekar, Hans C. Lee, Giovanni Palladini et al. Jun 01, 2026 pp. 7502-7502 10.1200/jco.2026.44.16_suppl.7502

7502 Background: Systemic AL amyloidosis is caused by deposition of misfolded amyloid fibrils produced by clonal plasma ce...

Postoperative pancreatic fistula after resection of pancreatic neuroendocrine tumors: Incidence, predictors, and clinical impact.

Oliver Overheu, Philipp Höhn, Doreen M. Zucha et al. Jun 01, 2026 pp. 4177-4177 10.1200/jco.2026.44.16_suppl.4177

4177 Background: Postoperative pancreatic fistula (POPF) remain a major source of morbidity after pancreatic surgery. Data...

Real-world analysis of targeted tumor genomic profiles in prostate cancer among Black and White men within the MedStar Health Network.

Rachel Alexander, Yanbao Xiong, Sravya Jannapureddy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22523

e22523 Background: Prostate cancer (PC) outcome disparities between White and Black men result from a combination of biolo...

Utilization and outcomes of minimally invasive resection in patients with neuroblastoma and Wilms tumor in a national cohort.

Courtney N. Day, Elizabeth B. Habermann, Stephanie F. Polites Jun 01, 2026 pp. 10043-10043 10.1200/jco.2026.44.16_suppl.10043

10043 Background: Tumor resection is a cornerstone of therapy for neuroblastoma (NB) and Wilms tumor (WT). Minimally invas...

Infectious complications in mantle cell lymphoma patients treated with CAR-T therapy: A real-world TriNetX analysis.

Anushree Venkatesh Murthy, Adithya Nagendran, Logesh Durairaj et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19088

e19088 Background: Chimeric antigen receptor T-cell therapy has significantly improved outcomes for patients with relapsed...

TP53 mutation adoption of stromal-adhesion/neuronal-like programs as a driver of stress adaptation and acute myelogenous leukemia cell survival.

Alexandra Thalberg, Jonathan Dan Andreadakis, Alexander Shkembi et al. Jun 01, 2026 pp. 6545-6545 10.1200/jco.2026.44.16_suppl.6545

6545 Background: TP53 -mutated AML is associated with early relapse and poor survival, highlighting th...

“Divergent paths in the right colon”: A 24-year analysis of appendiceal cancer versus cecal cancer mortality in the United States (1999-2023) and age and sex disparities.

Afzal Ahmed, Mohammed Misbahuddin, Abdul Shafi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15712

e15712 Background: Despite their anatomical proximity, appendiceal and cecal cancers represent distinct biological entitie...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page